Scott L. Burrows is CFO at Spyre Therapeutics, Inc. (SYRE). They have made 4 open-market trades across 2 companies since 2021, most recently 2026-10-01.
CIK 0001853327
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SYRE | 79,762 | $6.4M |
| ARQT | 59,115 | $1.7M |
| Total | $8.1M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SYRE | SELL · 10b5-1 | 2026-09-30 | 2026-10-02 | $90.47 | $2.3M | -16.4% | — | — |
| SYRE | SELL · 10b5-1 | 2026-09-01 | 2026-09-03 | $88.75 | $2.3M | +4.6% | +6.2% | — |
| SYRE | SELL · 10b5-1 | 2026-08-03 | 2026-08-05 | $95.57 | $717K | +1.4% | -13.8% | — |
| SYRE | SELL · 10b5-1 | 2026-07-01 | 2026-07-02 | $87.74 | $658K | +17.3% | +9.5% | +2.5% |
| SYRE | SELL | 2026-06-25 | 2026-06-26 | $87.13 | $1.3M | +15.0% | +16.5% | +1.4% |
| SYRE | SELL · 10b5-1 | 2026-06-01 | 2026-06-03 | $71.06 | $533K | +13.0% | +20.1% | +20.0% |
| SYRE | SELL · 10b5-1 | 2026-05-01 | 2026-05-01 | $71.37 | $892K | +11.8% | +3.2% | +48.6% |
| SYRE | SELL · 10b5-1 | 2026-04-01 | 2026-04-03 | $49.34 | $370K | +45.0% | +45.3% | +82.0% |
| SYRE | SELL · 10b5-1 | 2026-03-03 | 2026-03-03 | $40.65 | $102K | -0.6% | +18.5% | +75.5% |
| SYRE | SELL | 2025-09-02 | 2025-09-03 | $16.26 | $599K | -11.8% | -5.5% | +68.8% |
| SYRE | SELL | 2024-09-03 | 2024-09-05 | $28.17 | $1.0M | +2.5% | -1.1% | +0.6% |
| ARQT | SELL · 10b5-1 | 2023-03-06 | 2023-03-08 | $15.26 | $4K | -13.4% | -7.4% | -35.5% |
| ARQT | SELL · 10b5-1 | 2023-02-28 | 2023-03-02 | $15.91 | $29K | -27.4% | -29.4% | -52.5% |
| ARQT | SELL · 10b5-1 | 2022-03-04 | 2022-03-07 | $16.85 | $5K | +3.1% | +25.1% | +23.7% |
| ARQT | SELL · 10b5-1 | 2022-03-01 | 2022-03-03 | $17.75 | $7K | -6.5% | +24.9% | +18.7% |
| ARQT | SELL | 2021-12-27 | 2021-12-28 | $20.07 | $504K | -9.9% | -30.6% | -15.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.